Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis

被引:0
作者
Qing An
Zhihao Liu
机构
[1] Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University,Institute for Health Education
[2] Jiangsu Provincial Center for Disease Control and Prevention,undefined
来源
BMC Cancer | / 19卷
关键词
Advanced melanoma; PD-1/L1 blockade; CTLA-4 blockade; BRAF inhibitor; MEK inhibitor;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 237 条
[1]  
Little EG(2012)Update on the current state of melanoma incidence Dermatol Clin 30 355-361
[2]  
Eide MJ(2013)Targeting oncogenic drivers and the immune system in melanoma J Clin Oncol 31 499-506
[3]  
McArthur GA(2011)Cancer immunotherapy comes of age Nature 480 480-489
[4]  
Ribas A(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-264
[5]  
Mellman I(2007)PD-1 and PD-1 ligands: from discovery to clinical application Int Immunol 19 813-824
[6]  
Coukos G(2007)Melanoma biology and new targeted therapy Nature 445 851-857
[7]  
Dranoff G(2012)Melanoma: new insights and new therapies J Invest Dermatol 132 854-863
[8]  
Pardoll DM(2012)From genes to drugs: targeted strategies for melanoma Nat Rev Cancer 12 349-361
[9]  
Okazaki T(2011)Ipilimumab: first global approval Drugs 71 1093-1104
[10]  
Honjo T(2011)Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2517-2526